CSIMarket
 


Aclaris Therapeutics Inc   (ACRS)
Other Ticker:  
 
 

ACRS's Revenue Growth by Quarter and Year

Aclaris Therapeutics Inc 's Revenue results by quarter and year




ACRS Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
IV Quarter December - 17.57 7.75 1.50
III Quarter September - 9.28 19.02 1.66
II Quarter June - 1.87 1.53 1.82
I Quarter March 2.40 2.53 1.45 1.78
FY   2.40 31.25 29.75 6.76



ACRS Revenue first quarter 2024 Y/Y Growth Comment
Aclaris Therapeutics Inc reported decrease in Revenue in the first quarter 2024 by -5.22% to $ 2.40 millions, from the same quarter in 2023.
The decrease in the first quarter 2024 Aclaris Therapeutics Inc 's Revenue compares unfavorably to the Company's average Revenue doubling of 109.82%.

Looking into first quarter 2024 results within Major Pharmaceutical Preparations industry 111 other companies have achieved higher Revenue growth. While Aclaris Therapeutics Inc ' s Revenue decline of -5.22% ranks overall at the positon no. 2155 in the first quarter 2024.




ACRS Revenue ( Y/Y Growth %) 2024
2023 2022 2021
IV Quarter December - 126.71 % 416.67 % -5.06 %
III Quarter September - -51.21 % 1045.78 % 14.48 %
II Quarter June - 22.22 % -15.93 % -11.22 %
I Quarter March -5.22 % 74.48 % -18.54 % 26.24 %
FY   - 5.04 % 340.09 % 4.16 %

Financial Statements
Aclaris Therapeutics Inc 's first quarter 2024 Revenue $ 2.40 millions ACRS's Income Statement
Aclaris Therapeutics Inc 's first quarter 2023 Revenue $ 2.53 millions Quarterly ACRS's Income Statement
New: More ACRS's historic Revenue Growth >>


ACRS Revenue (Quarter on Quarter Growth %)

2024
2023 2022 2021
IV Quarter December - 89.33 % -59.25 % -9.64 %
III Quarter September - 396.26 % 1143.14 % -8.79 %
II Quarter June - -26.09 % 5.52 % 2.25 %
I Quarter March -86.35 % -67.35 % -3.33 % 12.66 %
FY (Year on Year)   - 5.04 % 340.09 % 4.16 %




Revenue first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #112
Healthcare Sector #307
Overall #2155

Revenue Y/Y Growth Statistics
High Average Low
1046.35 % 109.82 % -72.09 %
(Sep 30 2022)   (Mar 31 2020)
Revenue first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #112
Healthcare Sector #307
Overall #2155
Revenue Y/Y Growth Statistics
High Average Low
1046.35 % 109.82 % -72.09 %
(Sep 30 2022)   (Mar 31 2020)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Aclaris Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1144.63 % 72.59 % -86.35 %
(Sep 30 2022)  


ACRS's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2024 Aclaris Therapeutics Inc reported fall in Revenue sequentially by -86.35% to $ 2.40 millions, from $ 17.57 millions released in the previous reporting period.

It's not huge problem, as I. Quarter Revenue frequently seem to plunge in this quarter.

Within Major Pharmaceutical Preparations industry 135 other companies have achieved higher Revenue quarter on quarter growth. While Aclaris Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 2512.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #136
Healthcare Sector #361
Overall #2512
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #136
Healthcare Sector #361
Overall #2512
Revenue Q/Q Growth Statistics
High Average Low
1144.63 % 72.59 % -86.35 %
(Sep 30 2022)  


ACRS's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2024 Aclaris Therapeutics Inc realized fall in Revenue from the fourth quarter by -86.35% to $ 2.40 millions, from $ 17.57 millions declared in the previous quarter.

As we look into current shortcoming at the I. Quarter, we must presume, that usually I. Quarter 2024 results appear to be weaker then in the quarter before, Marcia Jesus, market consultant said.

Within Major Pharmaceutical Preparations industry 135 other companies have achieved higher Revenue quarter on quarter growth. While Aclaris Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 2512.


Aclaris Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2024)
12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
Cumulative Revenue 12 Months Ending $ 31.12 $ 31.25 $ 21.43 $ 31.17 $ 30.83
Y / Y Revenue Growth (TTM) 0.95 % 5.03 % -8.8 % 407.54 % 378.9 %
Year on Year Revenue Growth Overall Ranking # 19 # 9 # 46 # 2971 # 1545
Seqeuential Revenue Change (TTM) -0.42 % 45.81 % -31.24 % 1.11 % 3.61 %
Seq. Revenue Growth (TTM) Overall Ranking # 1184 # 154 # 79 # 2751 # 1511




Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Mar 31 2024 period, Aclaris Therapeutics Inc 's cumulative twelve months Revenue were $ 31 millions, company would post below average annual Revenue growth of 3.61% year on year, if the fiscal year would end at Mar 31 2024.
A slow-down in the Aclaris Therapeutics Inc 's Revenue growth from the 17.57% growth in Dec 31 2023.

Among companies within the Healthcare sector 2 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 9 to 19.

Revenue TTM Q/Q Growth Statistics
High Average Low
1055.48 %
129.73 %
-119.91 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 80
Healthcare Sector # 3
Overall # 19

Revenue TTM Y/Y Growth Statistics
High Average Low
1055.48 %
129.73 %
-119.91 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 80
Sector # 211
S&P 500 # 1184
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Mar 31 2024 period, Aclaris Therapeutics Inc 's cumulative twelve months Revenue were $ 31 millions, company would post below average annual Revenue growth of -119.91% year on year, if the fiscal year would end at Mar 31 2024.
A slow-down in the Aclaris Therapeutics Inc 's Revenue growth from the 17.57% growth in Dec 31 2023.

Among companies within the Healthcare sector 2 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 9 to 19.

Revenue TTM Q/Q Growth Statistics
High Average Low
1055.48 %
129.73 %
-119.91 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 80
Healthcare Sector # 3
Overall # 19

Revenue TTM Y/Y Growth Statistics
High Average Low
1055.48 %
129.73 %
-119.91 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 80
Sector # 211
S&P 500 # 1184




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ACRS's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for ACRS's Competitors
Revenue Growth for Aclaris Therapeutics Inc 's Suppliers
Revenue Growth for ACRS's Customers

You may also want to know
ACRS's Annual Growth Rates ACRS's Profitability Ratios ACRS's Asset Turnover Ratio ACRS's Dividend Growth
ACRS's Roe ACRS's Valuation Ratios ACRS's Financial Strength Ratios ACRS's Dividend Payout Ratio
ACRS's Roa ACRS's Inventory Turnover Ratio ACRS's Growth Rates ACRS's Dividend Comparisons



Companies with similar Revenue fall for the quarter ending Mar 31 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2024
Collegium Pharmaceutical inc -0.21%$ -0.215 millions
Mettler Toledo International Inc-0.30%$ -0.300 millions
3m Company-0.35%$ -0.349 millions
Icu Medical Inc-0.42%$ -0.423 millions
Lifeloc Technologies Inc -0.51%$ -0.513 millions
Regeneron Pharmaceuticals Inc -0.54%$ -0.541 millions
Envista Holdings Corporation-0.62%$ -0.622 millions
Orgenesis Inc -0.70%$ -0.704 millions
Vyne Therapeutics Inc -1.01%$ -1.010 millions
Ge Healthcare Technologies Inc -1.50%$ -1.502 millions
Baxter International Inc -1.56%$ -1.562 millions
Y mabs Therapeutics inc -1.58%$ -1.580 millions
Pacific Biosciences Of California Inc -1.59%$ -1.589 millions
Cartesian Therapeutics Inc -1.65%$ -1.650 millions
Viatris Inc -1.76%$ -1.762 millions
Ocuphire Pharma Inc -2.17%$ -2.173 millions
Vaso Corporation-2.51%$ -2.513 millions
Dentsply Sirona Inc -2.56%$ -2.556 millions
Alpha Pro Tech Ltd -2.78%$ -2.775 millions
Prestige Consumer Healthcare Inc -2.82%$ -2.817 millions
West Pharmaceutical Services Inc -2.99%$ -2.986 millions
Integra Lifesciences Holdings Corp-3.14%$ -3.144 millions
Accelerate Diagnostics Inc -3.17%$ -3.165 millions
National Research Corporation-3.18%$ -3.180 millions
Catheter Precision Inc -3.53%$ -3.529 millions
Elanco Animal Health Inc-4.14%$ -4.137 millions
Ptc Therapeutics inc -4.66%$ -4.657 millions
Foghorn Therapeutics Inc -4.88%$ -4.879 millions
Aclaris Therapeutics Inc -5.14%$ -5.142 millions
Avantor Inc -5.65%$ -5.645 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com